OncoMatch/Clinical Trials/NCT06783140
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
Is NCT06783140 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Nab paclitaxel and Gemcitabine for pancreatic cancer, advanced or metastatic.
Treatment: Nab paclitaxel · Gemcitabine · Cisplatin — This study will compare two different regimens for patients with BRCA1/2 or PALB2 mutated metastatic pancreatic cancer after progression on first-line FOLFIRINOX.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: BRCA1 mutation (somatic or germline)
BRCA1/2 or PALB2 mutation (somatic or germline)
Required: BRCA2 mutation (somatic or germline)
BRCA1/2 or PALB2 mutation (somatic or germline)
Required: PALB2 mutation (somatic or germline)
BRCA1/2 or PALB2 mutation (somatic or germline)
Disease stage
Metastatic disease required
Metastatic pancreatic adenocarcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: FOLFIRINOX or NALIRIFOX (FOLFIRINOX, NALIRIFOX) — first-line for metastatic disease
Clinical or radiographic progression on first-line FOLFIRINOX (or NALIRIFOX) for metastatic disease.
Cannot have received: cisplatin (cisplatin)
Patients may not have received prior cisplatin for their pancreatic cancer in any setting.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify